NEW: No-Cost StreetSmart Live! Events. This type of intellectual capital is usually not made available to the general public. Learn More
AGN:CSE; AGNPF:OTCQB; AGW:FSE

Algernon Pharmaceuticals Inc.

Algernon is a clinical stage drug re-purposing company that investigates safe, already approved drugs for new disease applications, moving them efficiently and safely into new human trials, developing new formulations and seeking new regulatory approvals in global markets. Algernon specifically investigates compounds that have never been approved in the U.S. or Europe to avoid off label prescription writing.
Algernon has filed new intellectual property rights globally for its lead drug NP-120 (Ifenprodil) for the treatment of respiratory diseases and is working to develop a proprietary injectable and slow release formulation.
AGN:CSE AGNPF:OTCQB AGW:FSE
View Company News
Visit Company Website

Expert Comments:

Pharma Greenlighted to Continue Multinational COVID-19 Study
(9/18/20)

This confirms the safety of NP-120, the drug Algernon Pharmaceuticals is evaluating in this human trial.
read more >

All Penny Stocks

(8/24/20)
"What a spectacular run junior biotech Algernon Pharmaceuticals Inc. has made since late-November. The stock run-up is largely predicated on one virus, COVID-19. With a brief pullback over the last few months, we think it is time to revisit this stock as the technical stars may be aligning for one more major push higher."
headshot of André Uddin

André Uddin, Mackie Research Capital

(8/19/20)
"We are initiating coverage of Algernon Pharmaceuticals Inc. with a Speculative Buy recommendation and a target price of $0.80/share. . .Algernon is focused on developing repurposed small molecules for new disease indications – these drug candidates have been already approved in ROW markets (but not approved in the U.S. or Europe). . .Algernon's lead product, ifenprodil (a marketed drug in Japan for circulatory disorders) is being repurposed for COVID-19, idiopathic pulmonary fibrosis (IPF) and chronic cough."

Pharmaceutical Firm Enrolls First US Patient in Phase 2b/3 Ifenprodil COVID-19 Trial
(8/17/20)

Algernon Pharmaceuticals reported it has enrolled the first U.S. patient in its multinational Phase 2b/3 human study of Ifenprodil for use in treatment of SARS-CoV-2.
read more >

Baystreet

(8/12/20)
"Algernon Pharmaceuticals Inc. is betting that this quiet and unassuming safe generic drug, Ifenprodil, may soon become a global blockbuster. . .the company recently announced the first patient has been enrolled in its multinational human Phase 2b/3 COVID trial of Ifenprodil. . .Phase 2b data are expected before 2020E."

Pharmaceutical Firm Doses First Patient in Phase 2 IPF and Chronic Cough Trial

(8/8/20)
Algernon Pharmaceuticals reported that the first patient has been dosed in the Phase 2 human study of Ifenprodil for treatment of idiopathic pulmonary fibrosis and chronic cough.
read more >

Biopharma Starts Enrollment Screening for Phase 2 Pulmonary Fibrosis, Cough Trial

(7/8/20)
In the study, Algernon Pharmaceuticals will test an existing drug that is being repurposed for these indications.
read more >

Biopharma's Multinational COVID-19 Study Receives US Ethics Approval

(6/30/20)
Algernon Pharmaceuticals is seeking approved participation from Australia, Romania and the Philippines as well.
read more >

FDA Greenlights Biopharma for Trial of Possible COVID-19 Therapeutic

(6/4/20)
Algernon Pharmaceuticals prepares to commence the Phase 2b study as soon as possible.
read more >

Small-Cap Pharma Fast-Tracking Repurposed Drug for Covid-19

(5/27/20)
Algernon Pharmaceuticals is quickly moving ahead with a multinational Phase 2b/3 trial for Ifenprodil.
read more >

Pharmaceutical Firm Gains Ethics Approval for Phase 2 Human IPF and Chronic Cough Trial

(5/10/20)
Algernon Pharmaceuticals received ethics approval in Australia for a Phase 2 human clinical study of NP-120 (Ifenprodil) for use in treatment of idiopathic pulmonary fibrosis and chronic cough.
read more >

Biotech Cleared for Phase 2b/3 Trial of NMDA Receptor Antagonist for COVID-19 Patients in Canada

(4/30/20)
Algernon Pharmaceuticals reported it received approval from Health Canada for a Phase 2b/3 multinational clinical study of Ifenprodil in COVID-19 patients to prevent progression to intubation and mechanical ventilation.
read more >

Experts Following This Company

Knox Henderson
headshot of André Uddin
 		André Uddin – Mackie Research Capital

The information provided above is from analysts, newsletters and other contributors. Please contact the company and visit its website before making an investment decision.See disclaimer for more details.

Investing Highlights
 
 Algernon Pharmaceuticals Inc. (OTC: AGNPF) (CSE: AGN) is one of the few companies still flying under the radar of the masses, potentially giving one of the last “ground floor” looks at a coronavirus stock before a pending breakout
 
 Algernon Pharmaceuticals Inc. (OTC: AGNPF) (CSE: AGN) already has a proven drug that has a strong safety history and was developed by one of the top names in biotech, Sanofi.
 
 Algernon Pharmaceuticals Inc. (OTC: AGNPF) (CSE: AGN) has already received positive Feedback from U.S. FDA for Ifenprodil COVID-19 Human Trial and is now approved for a Phase 2 clinical study in South Koreau cleared for a Phase 2b/3 human trial in CA
catalyst Calendar
Q2
2020
US FDA IND submission Phase 2b/3 May 15th, 2020
Q2
2020
First patient in Phase 2 study in South Korea – May 15th , 2020
Q2
2020
Ethics and regulatory approval for Phase 2 idiopathic pulmonary fibrosis (IPF) & chronic cough study
Algernon Pharmaceuticals Inc. Content
go
Corporate Presentation 2nd Quarter

 go
Fact Sheet April 2020